Skip to main content
. 2019 Jun 23;27(11):1701–1715. doi: 10.1038/s41431-019-0443-0

Table 3.

Diagnostic performance of index tests, stratified for high risk and baseline risk pregnancies

Fetal anomaly TP FP TN FN FPR Pr (FP|N) SPEC Pr (−|N) SENS Pr (+|A) PPV Pr (A|+) NPV Pr (N|−) ACC Pr (TP+TN|all)
n n n n n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI) n, % (95% CI)
High-risk pregnancies
 Proton™
  T21 145 4 1707 2 4/1711 1707/1711 145/147 145/149 1707/1709 1852/1858
0.23 (0.06–0.60) 99.7 (99–100) 98.6 (95–100) 97.3 (93–100) 99.8 (99–100) 99.6 (99–100)
  T18 48 5 1805 0 5/1810 1805/1810 48/48 48/53 1805/1805 1853/1858
0.28 (0.09–0.64) 99.7 (99–100) 100 (92–100) 90.5 (79–97) 100 (99–100) 99.7 (99–100)
  T13 6 6 1846 0 6/1852 1846/1852 6/6 6/12 1846/1846 1852/1858
0.32 (0.12–0.70) 99.6 (99–100) 100 (54–100) 50.0 (21–79) 100 (99–100) 99.6 (99–100)
  Turner 17 17 1821 3 17/1838 1821/1838 17/20 17/34 1821/1824 1838/1858
0.92 (0.54–2) 99.0 (98–100) 85.0 (62–97) 50.0 (32–68) 99.8 (99–100) 98.9 (98–100)
  T13, T18, or T21 199 15 1642 2 15/1657 1642/1657 199/201 199/214 1642/1644 1841/1858
0.91 (0.51–2) 99.0 (98–100) 99.0 (96–100) 92.9 (88–97) 99.8 (99–100) 99.0 (98–100)
 HiSeq™
  T21 146 7 1714 1 7/1721 1714/1721 146/147 146/153 1714/1715 1860/1868
0.41 (0.16–0.84) 99.5 (99–100) 99.3 (96–100) 95.4 (90–99) 99.9 (99–100) 99.5 (99–100)
  T18 49 5 1814 0 5/1819 1814/1819 49/49 49/54 1814/1814 1863/1868
0.27 (0.09–0.64) 99.7 (99–100) 100 (92–100) 90.7 (79–97) 100 (99–100) 99.7 (99–100)
  T13 7 3 1858 0 3/1861 1858/1861 7/7 7/10 1858/1858 1865/1868
0.16 (0.03–0.47) 99.8 (99–100) 100 (59–100) 70.0 (34–94) 100 (99–100) 99.8 (99–100)
  Turner 14 6 1842 6 6/1848 1842/1848 14/20 14/20 1842/1848 1856/1868
0.32 (0.12–0.71) 99.6 (99–100) 70.0 (45–89) 70.0 (45–89) 99.6 (99–100) 99.3 (98–100)
  T13, T18, or T21 202 15 1650 1 15/1665 1650/1665 202/203 202/217 1650/1651 1852/1868
0.90 (0.51–2) 99.0 (98–100) 99.5 (97–100) 93.0 (88–97) 99.9 (99–100) 99.1 (98–100)
Baseline risk pregnancies
 Proton™
  T21 5 3 1558 0 3/1561 1558/1561
0.19 (0.04–0.56) 99.8 (99–100)
  T18 0 3 1563 0 3/1566 1563/1566
0.19 (0.04–0.56) 99.8 (99–100)
  T13 0 4 1562 0 4/1566 1562/1566
0.26 (0.07–0.65) 99.7 (99–100)
  Turner 1 11 1554 0 11/1565 1554/1565
0.70 (0.35–2) 99.2 (98–100)
  T13, T18 or T21 5 10 1551 0 10/1561 1551/1561
0.64 (0.31–2) 99.3 (98–100)
 HiSeq™
  T21 5 0 1581 0 0/1581 1581/1581
0 (0–0.23) 100 (99–100)
  T18 0 3 1583 0 3/1586 1583/1586
0.19 (0.04–0.55) 99.8 (99–100)
  T13 0 4 1582 0 4/1586 1582/1586
0.25 (0.07–0.64) 99.7 (99–100)
  Turner 1 6 1579 0 6/1585 1579/1585
0.38 (0.14–0.82) 99.6 (99–100)
  T13, T18, or T21 5 7 1574 0 7/1581 1574/1581
0.44 (0.18–0.91) 99.5 (99–100)

Diagnostic performance of the two index tests (Proton™ NIPS and HiSeq™ NIPS) for T21, T18, T13; Turner syndrome and the detection of any of T13, T18, or T21 (rows) in high-risk pregnancies (top half) and baseline risk pregnancies (bottom half). The first four data columns represent the 2 × 2 table absolute frequencies observed as true positives (TP), false positives (FP), true negatives (TN), and false negative (FN), followed, for high-risk pregnancies, with the false positive rate (FPR), the clinical sensitivity (SENS), the clinical specificity (SPEC), the positive predictive value (PPV), the negative predictive value (NPV), and the clinical accuracy (ACC) while, for baseline risk pregnancies, only are shown the false positive rate (FPR) and the clinical specificity (SPEC). For each ratio, the corresponding table box contains the absolute ratio (n), the relative ratio (%), and the 95% confidence interval of the relative ratio (95% CI)